Biogen buys UK-based neuropathic pain drug developer for up to $675M
Jan 12, 2015, 00:00 AM
by
Michael Croft
Boston Business Journal | The Cambridge biotech
firm, known best for its drugs for multiple sclerosis, announced
the acquisition of Convergence Pharmaceuticals.
January 12, 2015 | The Cambridge biotech firm, known best for its drugs for multiple sclerosis, announced the acquisition of Convergence Pharmaceuticals. Boston Business Journal